Can Abilify Cause Chest Pain?
Chest pain is not a commonly reported adverse effect of Abilify (aripiprazole) in the FDA drug label or clinical literature, though cardiovascular effects including cardiac arrhythmias have been documented in overdose situations and in patients with specific risk factors.
Evidence from FDA Drug Label
The official FDA prescribing information for Abilify does not list chest pain as a common adverse reaction in therapeutic dosing 1. However, in overdose situations, clinically important cardiovascular signs have been observed, including:
- Atrial fibrillation
- Bradycardia
- Hypertension and hypotension
- Tachycardia
- QRS complex prolongation
- QT prolongation 1
These cardiac effects occurred in overdose cases (alone or in combination with other substances) and required cardiac monitoring when QT interval prolongation was present 1.
Cardiovascular Safety Profile
Aripiprazole has a relatively favorable cardiac safety profile compared to other antipsychotics, particularly regarding QTc prolongation risk 2. A systematic review and meta-analysis found that:
- Mean ΔQTc interval was actually decreased with aripiprazole treatment
- QTc prolongation risk was lower compared with both placebo and active control antipsychotics
- Aripiprazole has limited affinity for the delayed rectifier potassium current (the mechanism behind most drug-induced QTc prolongation) 2
However, aripiprazole has not been associated with QTc prolongation or torsades de pointes in most studies, making it a preferred choice when antipsychotic treatment is needed in patients with arrhythmia risk 3.
Documented Cardiac Adverse Events
While rare, specific cardiac events have been reported with aripiprazole:
- Atrial fibrillation: One case report documented new-onset atrial fibrillation in a patient with multiple concomitant risk factors (hypertension, CYP2D6 polymorphism, rapid titration regimen) 4
- Non-cardiogenic pulmonary edema: A case of pulmonary edema with bilateral pleural effusion was reported, potentially related to drug interaction with sertraline (a CYP2D6 inhibitor) increasing aripiprazole levels 5
Clinical Context for Chest Pain Evaluation
If a patient on Abilify presents with chest pain, the evaluation should focus on:
- Cardiac causes: Obtain ECG to assess for arrhythmias, QTc prolongation, or ischemic changes 6
- Pulmonary causes: Consider rare hypersensitivity pneumonitis, which has been reported with aripiprazole 7
- Non-cardiac causes: Musculoskeletal, gastrointestinal (especially esophageal), or anxiety-related chest pain are more common than drug-induced cardiac effects 8
- Drug interactions: Assess for CYP2D6 inhibitors that may increase aripiprazole levels 5
Risk Factors Requiring Caution
Baseline and steady-state ECG monitoring is recommended in patients at high risk for cardiac complications, including those with 2:
- Pre-existing cardiac disease
- Electrolyte abnormalities
- Concomitant QTc-prolonging medications
- Family history of sudden cardiac death
- Elderly patients with multiple cardiovascular risk factors 4
Bottom Line
Chest pain is not a typical side effect of therapeutic Abilify use. If chest pain occurs, standard cardiac evaluation is warranted to rule out acute coronary syndrome or arrhythmias, but the chest pain is more likely related to other causes rather than the medication itself. Aripiprazole remains one of the safer antipsychotics from a cardiovascular standpoint, particularly regarding arrhythmia risk 3, 2.